Literature DB >> 29668513

Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy.

Berna A Yildirim1, Nese Torun2, Ozan C Guler1, Cem Onal1.   

Abstract

PURPOSE: The aim of this study was to evaluate the prognostic importance metabolic tumor volume (MTV), total lesion glycolysis (TLG), and standardized uptake value (SUV) in patients with esophageal cancer treated with definitive chemoradiotherapy. PATIENTS AND METHODS: Seventy-two esophageal cancer patients treated with definitive chemoradiotherapy [57 (79%) patients] or definitive radiotherapy [15 (21%) patients] were retrospectively analyzed. The regions equal to or greater than SUV of 2.5 were selected to delineate MTV and TLG was calculated by multiplying the mean SUV by the MTV of the primary lesions. The overall survival (OS) and disease-free survival (DFS) were evaluated for all patients and also patients with squamous cell carcinoma.
RESULTS: The median survival time was 13.4 months (range: 1.8-119.3 months) for all patients. Maximum SUV, mean SUV, MTV, and TLG values were significantly higher in patients with extensive T-stage (T3-T4) compared with patients with T1-T2 disease. Patients with regional lymph node metastasis had significantly higher MTV and TLG values compared with patients with no lymph node metastasis. On multivariate analysis, MTV, TLG, presence of lymph node metastasis, and lack of concurrent chemotherapy were negative significant prognostic factors for OS and DFS for the entire cohort and for patients with squamous cell carcinoma esophageal cancer.
CONCLUSION: Metabolic volumes (MTV and TLG), regional lymph node metastasis, and concurrent chemotherapy are major prognostic factors for DFS and OS in patients with esophageal carcinoma. In addition, MTV and TLG are important in predicting nodal metastasis, and together with metabolic volumes, SUV are associated significantly with local tumor invasion.

Entities:  

Mesh:

Year:  2018        PMID: 29668513     DOI: 10.1097/MNM.0000000000000837

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  Prognostic Significance of FDG PET/CT in Esophageal Squamous Cell Carcinoma in the Era of the 8th AJCC/UICC Staging System.

Authors:  Hyunjong Lee; Kyung Soo Lee; Yang Won Min; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim; Joon Young Choi
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

2.  The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas.

Authors:  Ulku Korkmaz; Muhammet Bekir Hacioglu; Osman Kostek; Necdet Sut; Hilmi Kodaz; Bulent Erdogan; Funda Ustun; Mert Saynak; Ebru Tastekin; Irfan Cicin; Gulay Durmus-Altun
Journal:  Pol J Radiol       Date:  2020-05-15

3.  A five-gene signature to predict the overall survival time of patients with esophageal squamous cell carcinoma.

Authors:  Wenwu He; Qunlun Yan; Liangmin Fu; Yongtao Han
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

4.  Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma.

Authors:  Lu-Meng Zhou; Ling-Ling Yuan; Yan Gao; Xu-Sheng Liu; Qin Dai; Jian-Wei Yang; Zhi-Jun Pei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-27       Impact factor: 9.236

5.  Tumor microenvironment characterization in esophageal cancer identifies prognostic relevant immune cell subtypes and gene signatures.

Authors:  Yuhong Zhang; Minqi Zhu; Junxian Mo; Lei Xian
Journal:  Aging (Albany NY)       Date:  2021-12-26       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.